Kidney Cancer Clinical Trial

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Summary

NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are:

what is an appropriate dose to be given to patients?
are the side effects of treatment manageable?

Participants will be evaluated for participation in the study. Patients who are treated will receive an intravenous infusion of NPX267 every three weeks if their disease has not progressed. Patients will be closely monitored by the treating physician.

View Full Description

Full Description

This trial is divided into two parts. The first part (dose escalation) will test different doses of drug to find a dose for part two. In the second part (dose expansion), more patients will be tested to see if the drug has an effect on patient's tumors.

Throughout the study, data will be collected to characterize the clinical activity of the drug. Samples of blood will be taken to help in an understanding of how the drug behaves in the body by assessing the amount of drug in the blood over time (pharmacokinetics), and changes in blood components (pharmacodynamics and safety). Tumor imaging by computed tomography (CT) or magnetic resonance imaging (MRI) will be done about every nine weeks to assess NPX267 impact on tumor growth.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically confirmed recurrent, metastatic solid tumor refractory to standard of care therapy in one of the following indications: Part 1a: non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), cholangiocarcinoma (CCA), pancreatic cancer (PDAC), urothelial carcinoma (UCC), gastric/gastroesophageal carcinoma, triple negative breast carcinoma, endometrial carcinoma, cervical cancer, osteosarcoma, and prostate cancer
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Normal bone marrow, kidney and liver function
Willing to use highly effective contraceptive measures throughout the trial

Exclusion Criteria:

Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia, chronic neuropathy > 6 months, or changes in skin pigmentation
Have known or suspected brain metastases, unless they are clinically stable
Known autoimmune disease requiring immunosuppressive treatment requiring the equivalent of more than 10 mg prednisone daily
History of grade 3 immune-related pneumonitis or colitis

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

131

Study ID:

NCT05958199

Recruitment Status:

Recruiting

Sponsor:

NextPoint Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Johns Hopkins University
Baltimore Maryland, 21287, United States More Info
Danielle Wendler
Contact
410-502-5140
[email protected]
Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Justin Gainor, MD
Contact
617-724-4000
[email protected]
Albert Einstein Medical College
New York New York, 10461, United States More Info
Gunnar Lauer
Contact
[email protected]
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States More Info
MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Aung Naing, MD
Contact
713-563-3885
[email protected]
NEXT Oncology-San Antonio
San Antonio Texas, 78229, United States More Info
Cheryl Merendon
Contact
210-580-9521
[email protected]
NEXT Oncology-Fairfax
Fairfax Virginia, 22031, United States More Info
Blake Patterson
Contact
703-783-4505
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

131

Study ID:

NCT05958199

Recruitment Status:

Recruiting

Sponsor:


NextPoint Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.